

Certificate of Mailing (37 C.F.R. §1.10):

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV291841502US) in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 11th day of March 2005.

Rachel Potash

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Gerald McMahon, et al.

Serial No.: 10/713,201

Confirmation No.: 9575

Filed: November 17, 2003

For: HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS

Mail Stop AMENDMENT Honorable Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

1. Amendment and Response;

2. Return Postcard;

3. Total Fee Due \$0.00

11 pages:

Group Art Unit: 1624

Examiner: Raymond, Richard L.

1 postcard; and

Deposit Account.

Respectfully submitted,

Date: 03 4 65

Agent For Applicants
Registration No. 53,225

Agouron Pharmaceuticals, Inc./A Pfizer Company Patent Department 10777 Science Center Drive San Diego, California 92121

Phone: (858) 622-3087 Fax: (858) 678-8233 PC23456C Response to Office Action

~EV291841502US

Certificate of Mailing (37 C.F.R. §1.10):
I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV291841502US) in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 11th day of March 2005.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Gerald McMahon, et al.

Serial No.: 10/713,201

Confirmation No.: 9575

Filed: November 17, 2003

For: HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS

Group Art Unit: 1624

Examiner: Raymond, Richard L.

Mail Stop AMENDMENT Honorable Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE

Sir:

In response to the Office action mailed December 17, 2004, please amend the above-identified application as follows:

- Amendments to the Specification begin on page 2 of this paper.
- Amendments to the Claims are reflected in the listing of claims, which begins on page 3 of this paper.
- Remarks begin on page 6 of this paper.